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Efficacy of injectable platelet-rich 
fibrin in the erosive oral lichen planus: 
a split-mouth, randomized, controlled 
clinical trial*
Objective: Our study compared the effects of injectable platelet-rich fibrin 
(i-PRF) with those of corticosteroids in the treatment of erosive oral lichen 
planus (EOLP). Methodology: This split-mouth study included 24 individuals 
diagnosed histopathologically with bilateral EOLP. One bilateral lesion was 
injected with i-PRF, whereas the other was injected with methylprednisolone 
acetate in four sessions at 15-day intervals. Visual analog scale (VAS) for pain 
and satisfaction, oral health impact profile scale-14, and the lesion size were 
used. Results: The intragroup comparisons showed a significant decrease 
in VAS-pain and lesion size in both the i-PRF group (from 81.88±17.74 
to 13.33±18.34, and from 4.79±0.41 to 1.88±1.08, respectively) and 
the corticosteroid group (from 80.21±17.35 to 23.33±26.81, and from 
4.71±0.46 to 2.21±1.35, respectively) in the 6th month compared to baseline 
(p<0.001). Moreover, VAS-satisfaction increased significantly in both the 
i-PRF group (from 26.67±17.8 to 85.63±16.24) and the corticosteroid group 
(from 28.33±17.05 to 74.38±24.11) in the 6th month compared to baseline 
(p<0.001). However, no significant difference in any value occurred in the 
intergroup comparisons. Conclusion: In patients with EOLP, both methods 
decreased pain and lesion size similarly, and both increased satisfaction. 
Therefore, the use of i-PRF may be considered an option in cases refractory 
to topical corticosteroid therapy. Biochemical and histopathological studies 
are required to reveal the mechanism of i-PRF action in EOLP treatment.
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Introduction
Oral lichen planus (OLP) is a chronic inflammatory 
immune mediated disease of unknown cause, in 
which T lymphocytes attack multi-layer flat epithelial 
cells.1,2 Most infiltrating lymphocytes seen in OLP 
are CD8+, so the condition probably results from 
a cytotoxic autoimmune response.3 Furthermore, 
CD4+ T lymphocytes increase the cytotoxicity of 
CD8+ lymphocytes by infiltrating OLP lesions. The 
buccal mucosa, tongue and gingiva are the most 
frequently affected regions in the oral cavity, and 
the lesions can occur symmetrically, bilaterally, or 
unilaterally. Reticular and papular OLP lesions are 
often asymptomatic; however, atrophic and erosive 
oral lichen planus (EOLP) forms can negatively affect 
patients’ quality of life, causing sensitivity, burning 
symptoms, and discomfort.4
The treatment for OLP lesions include different 
pharmacological agents, such as corticosteroids, 
immunosuppressives, retinoids and metronidazole.5 
Corticosteroid treatment, in particular, can lead to 
several side effects, such as pain, bleeding, ulceration, 
secondary infections, perilesional linear atrophy, 
hypopigmentation, allergic reactions, calcification 
and granuloma.4,5 Consequently, medical treatment 
may include different alternative therapies, such as 
biostimulation with diode laser, photodynamic therapy 
based on methylene blue, psoralen and ultraviolet A 
therapy (a form of photochemotherapy treatment), 
ozone therapy and herbal remedies with anti-
inflammatory properties (e.g., aloe vera, lycopene).1
Platelet-rich fibrin (PRF) is a three-dimensional 
fibrin network that accelerates wound healing, 
immunity and neovascularization. It contains host 
immune defense cells (leukocytes) and promotes three 
important stages of wound healing: angiogenesis, 
immune response and epithelial proliferation.6 In one 
study comparing PRF and connective tissue graft to 
treat gingival recession, the levels of gingival crevicular 
fluid proinflammatory markers (interleukin (IL)-1β and 
matrix metalloproteinase-8) were significantly lower in 
the PRF group.7 Similar to conventional PRF, injectable 
PRF (i-PRF) increases the number of leukocytes and 
stimulates growth factor release.8 In another study, 
direct injection of the lesion with growth factor-rich 
plasma, which is a first generation blood product and 
contains anticoagulants, decreased pain and improved 
quality of life in patients with OLP.9
The i-PRF is an autogenous product that acts as a 
growth factor release system involving transforming 
growth factor- β (TGF-β), platelet-derived growth 
factor (PDGF), and vascular endothelial growth factor 
(VEGF).10,11 It has been shown to have an important 
regenerative role in human skin fibroblasts.12 The 
i-PRF exhibits a supportive regenerative property 
for osteoblastic differentiation and reparative dentin 
stimulation in human dental pulp cells,13 besides 
attenuating the inflammatory state induced by 
lipopolysaccharides.13 Due to its bioactive nature, 
i-PRF can be used in combination with collagen-based 
biomaterials to increase healing activity.10 Also, it can 
be mixed with bone grafts and used to graft bone 
defects in Dentistry,11 and to treat facial cutaneous 
tracts secondary to medication-related osteonecrosis 
of the jaw14 and cell mucositis of the oral cavity.15
Due to the numerous positive features of i-PRF, 
we aimed to evaluate its effect on EOLP lesions and 
quality of life in this present study. 
Methodology
 This randomized, controlled, prospective, split-
mouth study involved patients diagnosed both clinically 
and histopathologically with bilateral EOLP. The study 
protocol was approved by the Clinical Research Ethics 
Committee of Bezmialem Vakıf University (2017-
12/20). Individuals referred to the Periodontology 
Department of the Faculty of Dentistry at Bezmialem 
Vakıf University were informed about the treatment 
protocol, and written consent was obtained from 
the individuals in accordance with the Declaration of 
Helsinki. The study was registered on ClinicalTrials.gov 
(NCT03265093) and was conducted from June 2017 to 
September 2019. Figure 1 shows the study flow chart.
Patient selection
To ensure 80% power (1 - β) with a 95% confidence 
interval (α=0.05), and an effect size of 1.01, and 
considering the lesion size scores at the 2nd month 
(according to Thongprasom), the study size was 
estimated as 17 patients per group.16 Therefore, 24 
individuals were included in case of any dropout.
Our study included systemically healthy volunteers 
who were diagnosed clinically and histopathologically 
with bilateral EOLP according to Andreasen 
classification17 and World Health Organization criteria18, 
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and who were refractory to topical corticosteroid 
therapy. The punch biopsy method was used for 
histopathological evaluation, and no volunteers had 
received lichen planus treatment in the previous 3 
months. The baseline and 2nd month follow-up data for 
13 patients were included in our previous pilot study.19
The exclusion criteria were: age younger than 18 
years, pregnancy or breastfeeding, systemic disease 
(e.g., diabetes, Cushing’s syndrome), coagulation 
disorders, smoking, infectious disease (e.g., hepatitis), 
use of anticoagulant drugs, psychiatric problems, 
dysplasia upon histopathology16 and OLP manifestations 
in other mucous membranes simultaneously.
Preparation of i-PRF
Venous blood was collected from each patient 
using a 20-mL syringe and placed in two plastic i-PRF 
tubes (10 mL each, without anticoagulant). The tubes 
were centrifuged with Intra-spin system, Intra-Lock 
centrifuge (Process for PRF, Boca-Raton, FL, EUA) at 
700 rpm for 3 min (47 g force) to obtain i-PRF. The 
i-PRF was then drawn into dental injectors with 27 
gauge needle tips in preparation for injection.
Application protocol
A topical anesthetic gel containing 20% benzocaine 
(VISION Pat Gel; Anadolu Dis Deposu, Istanbul, 
Turkey) was applied to the EOLP region before the 
procedure was started. In the same session, one of 
the bilateral EOLP lesions was injected with i-PRF 
and the other with methylprednisolone acetate. Both 
injections were administered during four sessions and 
had a 15-day interval between each session.
i-PRF Group; i-PRF obtained as a result of 
centrifugation was drawn into a dental injector with 
27-gauge needle tip in preparation for injection. It was 
Figure 1- Flow chart
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injected at four different endpoints at the periphery 
of the lesion, as described in the study by Pinas, et 
al.9 (2017).
Corticosteroid Group; Methylprednisolone acetate 
(40 mg/mL Depo-medrol; Eczacibasi, Istanbul, Turkey) 
was applied with an insulin syringe (29-gauge needle) 
at four different endpoints into the subepithelial tissue 
underlying the lesion and adjacent to the normal 
mucosa.20 Each injection was 0.2 mL per session.
Evaluation of visual analog scale-pain, visual 
analog scale-satisfaction, oral health impact 
profile-14 and thongprasom classification
The effects of pharmaceutical and alternative 
therapies were evaluated using the visual analog 
scale (VAS) for pain21 and satisfaction,22 the 14-item 
oral health impact profile (OHIP-14),23 and objective 
evaluation of lesion size.24
The participants were asked to determine the 
degree of complaint and their satisfaction using a 
100-unit chart for VAS. In the VAS-pain scale, 0 points 
indicated no complaints, and 100 reflected the most 
severe complaint. Likewise, 0 points on the VAS-
satisfaction scale indicated no satisfaction and 100 
points denoted very good satisfaction. The scales were 
performed just before the first injection, immediately 
after the last injection session, and at the 1st, 2nd, and 
6th months of the control sessions.
The OHIP-14 questionnaire was used to evaluate 
quality of life consisting in seven domains and with 
two questions in each domain.23 Patients answered 
questions about discomfort and inadequacies 
regarding oral health, assigning a score between 0 and 
4 for each question, therefore, a total score between 0 
and 56 was estimated. The lowest score of 0 indicated 
a very good quality of life, whereas the highest score 
of 56 reflected a very poor quality of life. Scores higher 
than 14 indicated poor oral health-related quality of 
life.23 The scale was adapted for Turkish patients by 
Mumcu, et al.25 (2006), who reported a Cronbach’s 
α-value of 0.94. The questionnaire was administered 
immediately before the first injection, and at the 1st, 
2nd, and 6th month control sessions.
The width and length of the erosive lichen planus 
surface on both sides were marked on the abaisse 
tongue. The points marked were measured using a 
digital calliper (150 mm digital calliper, Alpha Tools®, 
Oakland, NJ, USA) with a sensitivity of 0.01 mm. The 
calculated surface areas were evaluated according 
to the method by Thongprasom, et al.24 (2003). 
Specifically, a score between 0 and 5 points was 
assigned (score 0: no lesion, score 1: only white stria, 
score 2: < 1 cm2 white line with erythematous area, 
score 3: > 1 cm2 white line with erythematous area, 
score 4: < 1 cm2 white line with erosive area, score 5: 
> 1 cm2 white line with erosive area). The evaluation 
was performed just before the first injection, and at 
the 1st, 2nd, and 6th month control sessions. 
Randomization
The lesions of the patients were randomly divided 
into two groups by an independent researcher (T.U.) 
using a computer-assisted randomization table (www.
randomizer.org; Copyright© 1997–2011 by Geoffrey C. 
Urbaniak and Scott Plous). Assignments were hidden 
from the physician performing the treatment (Z.B.Ö.) 
until the first treatment session, from the physician 
recording the measurements throughout the study, 
and from patients throughout the study.
Statistical analysis
Descriptive statistics were used to define continuous 
variables, whereas the Shapiro-Wilk test was used to 
evaluate the normality of data distribution. The Mann-
Whitney U test was conducted to assess intergroup 
comparisons, and, the Friedman test was used to 
the intragroup comparisons values (time-varying 
multiple dependent variables), followed by post-hoc 
pairwise comparisons with the Bonferroni-corrected 
Wilcoxon’s signed-rank test. Parameters with 
p<0.05 were considered significant. In the case of 
Bonferroni-corrected Wilcoxon tests of the VAS-pain 
and VAS-satisfaction scores, p<0.005 was considered 
significant, also, in the case of Thongprasom and 
OHIP-14 assessments, p<0.008 was considered 
significant. MedCalc Statistical Software version 12.7.7 
(MedCalc Software bvba, Ostend, Belgium; http://
www.medcalc.org) was used for the analyses.
Results
Our study included 24 patients (14 women and 
10 men) between 34 and 76 years old (mean: 52.25 
years) with bilateral EOLP. To the best our knowledge, 
the subjects reported no systemic side effects during 
the injections or the follow-up period. Figure 2 shows 
the intraoral view of a patient with OLP before and 
after the injections.
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The intergroup comparison showed no significant 
difference between the i-PRF group and the 
corticosteroid group regarding VAS-pain values 
(p>0.05 by the Mann-Whitney U test). On the 
other hand, the intragroup comparisons showed a 
statistically significant difference among all time 
measurements of the VAS-pain values in both i-PRF 
and corticosteroid groups (p<0.05 by the Friedman 
test). According to the post-hoc pairwise comparisons, 
the median values after the last injection and at 1st, 
2nd and 6th months were statistically lower than the 
baseline values (p<0.005 by the Wilcoxon test with 
Bonferroni correction) when comparing VAS-pain 
levels of the i-PRF and corticosteroid groups within 
each group. The 1st and 2nd month VAS-pain levels 
were significantly lower than the levels after the last 
injection in both groups, and the 6th month VAS-pain 
levels in the i-PRF group were significantly lower than 
those after the last injection. Moreover, the 2nd month 
VAS-pain levels in the i-PRF group were significantly 
lower than the 1st month levels (p<0.005 by the 
Wilcoxon test with Bonferroni correction; Table 1).
The intergroup comparison also showed no 
significant difference between the i-PRF group and 
the corticosteroid group regarding VAS-satisfaction 
values (p>0.05 by the Mann-Whitney U test). The 
intragroup comparisons, in turn, showed a statistically 
significant difference among all time measurements 
of the VAS-satisfaction values in both the i-PRF and 
the corticosteroid groups (p<0.05 by the Friedman 
test). According to the post-hoc pairwise comparisons, 
the median values after the last injection and at 1st, 
2nd and 6th months were significantly higher than the 
baseline median values (p<0.005 by the Wilcoxon 
test with Bonferroni correction) when comparing the 
VAS-satisfaction levels of the i-PRF and corticosteroid 
groups within the groups. The 1st and 2nd month VAS-
satisfaction levels were significantly higher in both 
groups compared to levels after the last injection, 
whereas the 6th month VAS-satisfaction levels in the 
i-PRF group were significantly higher than those levels 
after the last injection (p<0.005 by the Wilcoxon test 
with Bonferroni correction; Table 1).
Finally, the intergroup comparison showed no 
Figure 2- The picture comparing (1) injectable platelet-rich fibrin (i-PRF) and (2) corticosteroid injection (a) at baseline, and at the (b) 1st, 
(c) 2nd, and (d) 6th months after treatment
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significant difference between the groups regarding 
Thongprasom baseline measurements (p>0.05 
by the Mann-Whitney U test). On the other hand, 
the intragroup comparisons showed a statistically 
significant difference between all time measurements 
of the Thongprasom values in both the i-PRF group 
and the corticosteroid group (p<0.05 by the Friedman 
test). According to the post-hoc pairwise comparisons, 
the Thongprasom 1st, 2nd and 6th month median values 
were significantly lower in both groups compared to 
the baseline median values (p<0.008 by the Wilcoxon 
test with Bonferroni correction; Table 2). 
We observed no statistically significant difference 
between the groups regarding OHIP-14 measurements 
(p<0.05 by the Friedman test). According to the 
post-hoc pairwise comparisons, the median OHIP-14 
values were significantly lower in all months compared 
to baseline values (p<0.008 by the Wilcoxon test 
VAS-pain VAS-satisfaction Levels
i-PRF Group Corticosteroid Group i-PRF Group
Corticosteroid 
Group
Mean±SD Mean±SD p1 Mean±SD Mean±SD p1






85 (40-100) 80 (40-100) 27.5 (0-70) 30 (0-70)























10 (0-60) 10 (0-90) 90 (50-100) 80 (10-100)
p* <0.001 <0.001 <0.001 <0.001
Table 1- Comparisons of VAS-pain and VAS-satisfaction values with intragroup and intergroup
*Friedman test p-value (intragroup); statistical significance (p<0.05) marked in bold.
1Mann-Whitney U test p-value (intergroup). 
a Statistical significance compare to baseline,
b Statistical significance compare to after the last injection,
c Statistical significance compare to 1st month, using the Wilcoxon test with Bonferroni-correction (p<0.005).
Abbreviations: VAS, visual analog scale; i-PRF, injectable platelet-rich fibrin; SD, standard deviation; Med, median; Min, minimum; Max, 
maximum.
i-PRF Group Corticosteroid Group p1
Mean±SD Mean±SD

















1.5 (1-5) 2 (1-5)
p* <0.001 <0.001
Table 2- Comparisons of Thongprasom levels with intragroup and intergroup
*Friedman test p-value (intragroup); statistical significance (p<0.05) marked in bold.
 1Mann-Whitney U test p-value (intergroup).
 a Statistical significance compare to baseline, using the Wilcoxon test with Bonferroni-correction (p<0.008). 
Abbreviations: VAS, visual analog scale; i-PRF, injectable platelet-rich fibrin; SD, standard deviation; Med, median; Min, minimum; Max, 
maximum.
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with Bonferroni correction; Table 3). Moreover, the 
2nd month OHIP-14 measurements were significantly 
lower than the 1st month measurements in the patients 
(p<0.008 by the Wilcoxon test with Bonferroni 
correction; Table 3).
Discussion
In our study, VAS-pain levels after the last 
injection in the i-PRF group were lower, and VAS-
satisfaction levels were higher. However, the i-PRF and 
corticosteroid groups showed no difference regarding 
VAS-pain, VAS-satisfaction, or lesion size. In contrast, 
the 6th month VAS-pain and VAS-satisfaction values 
in the i-PRF group differed significantly from both the 
baseline levels and the levels after the last injection.
Topical corticosteroids can be used to minimize 
adverse drug effects, since they only affect the lesion 
and the surrounding tissues. This is the reason why 
topical corticosteroid administration is considered the 
first-choice treatment in OLP, rather than a systemic 
treatment.26 Intralesional applications may obtain 
a better response when topical corticosteroids are 
ineffective in resolving and healing the lesion.9,20,26 
Studies have proven the effectiveness of intralesional 
corticosteroid applications in OLP management; 
however, their continuous and long-term use is 
associated with many systemic side effects.27,28 Thus, 
a need for a more effective and efficacious treatment 
of erosive OLP with few or no side effects emerges. 
Studies toward this goal has focused on the use of 
biomolecules, such as platelet-rich plasma (PRP) and 
platelet-rich growth factor (PRGF), which are rich 
in growth factors and act as a continuous release 
scaffold. The use of biomolecules to treat lichen 
planus is growing.9,27,29,30 In our study, we compared 
the effectiveness of intralesional application of 
Methylprednisolone acetate, which is a corticosteroid 
and i-PRF, an autologous factor, in bilateral EOLP 
lesions.
Oral health problems can cause pain and discomfort, 
and lead to problems with eating and drinking, social 
relations, appearance, and self-reliance. The OLP is 
a severe disease with symptoms and complications 
that affect individuals’ lives.9,31,32 Patients with have 
poor quality of life,31 and high VAS-pain values 
are associated with increased OHIP-14 score in 
individuals with EOLP.33 However, the VAS-pain and 
OHIP-14 values of individuals with OLP decrease 
after topical corticosteroid treatment.32 Ahuja, et al.27 
(2020) compared intralesional PRP and triamcinolone 
acetonide applications in EOLP lesions by measuring 
changes in VAS-pain values during 4 months of 
follow-up. They reported that both applications were 
successful and had similar effectiveness. Likewise, 
Bennardo, et al.30 (2021) compared the 4-week results 
of PRF and triamcinolone acetonide injected therapies 
in patients with OLP patients in a split mouth study. 
The authors reported a mean decrease of 47.6% in 
the VAS score for PRF-treated sites; the decrease in 
the score for the triamcinolone acetonide–treated sites 
was 40%. The study reported no statistically significant 
difference between the groups; however, the authors 
stated that PRF is as effective as triamniconole 

















Table 3- Comprasions of OHIP-14 values
*Friedman test p-value (intragroup); statistical significance (p<0.05) marked in bold.
a Statistical significance compare to baseline, 
b Statistical significance compare to 1st month, using the Wilcoxon test with Bonferroni-correction (p<0.008).
Abbreviations: VAS, visual analog scale; OHIP-14, Oral Health Impact Profile-14; SD, standard deviation; Med, median; Min, minimum; 
Max, maximum.
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lesions. Our study showed that baseline VAS-pain and 
OHIP-14 levels were high and that VAS-pain and OHIP-
14 values decreased significantly at the 1st, 2nd, and 6th 
months. Similarly, VAS-satisfaction values increased in 
both treatment groups compared to baseline values.
In previous studies, EOLP lesion sizes decreased 
significantly after topical or injected corticosteroid 
applications, as defined in terms of Thongprasom 
values.16,30,32 Studies have compared intralesional 
PRP and triamcinolone acetonide applications in EOLP 
lesions considering the changes in lesion sizes. PRP 
application has also provided efficacy similar to that of 
triamcinolone acetonide.27 In their split-mouth study 
of injectable treatments, Bennardo, et al.30 (2021) 
reported a mean decrease of 59.8% in the lesion size 
for PRF-treated sites and of 59.2% for triamniconole 
acetonoide-treated sites. Despite the inexistence of 
statistical difference between the groups regarding 
reduction in lesion size, the authors stated that PRF 
had effectiveness similar to that of triamcinolone 
acetonide. Corroborating these studies, our study 
showed a significant decrease in EOLP lesion size in 
both the i-PRF and corticosteroid groups at the 1st, 2nd 
and 6th months when compared with baseline.
Oral lichen planus lesions show higher expression 
levels of inflammatory cytokines, including toll-like 
receptor/nuclear factor-κB p65, IL-1β, IL-6 and tumor 
necrosis factor-α.34 Zhang, et al.35 (2020) reported that 
i-PRF can reduce the inflammatory response caused 
by lipopolysaccharides to some extent. The authors 
emphasized the potential anti-inflammatory role of 
i-PRF, since they found out that it inhibited the TLR4 
(an inflammatory stimulation activator) and p-p65 (a 
key factor of the classical inflammatory-related NF-kB 
signaling pathway). Thus, the use of i-PRF may support 
healing by reducing the immune response and be an 
appropriate clinical strategy to alleviate the symptoms 
of OLP.35 Pinas, et al.29 (2018) found that OLP lesions 
may lack certain growth factors, which could be 
eliminated by local application of autologous factors 
(e.g., PRGF). The authors reported this application 
improved cell functions and restored cell-matrix 
communication. Like PRGF, i-PRF gradually releases 
growth factors, thus reducing inflammation in the 
environment, and these actions facilitate proper tissue 
healing and modification of the cellular environment.8 
In our study, the positive effects of i-PRF on VAS-pain 
and VAS- satisfaction levels and on lesion sizes may 
be due to all these features.
We decided not to perform biopsy after the 
treatments, since a mechanical trauma can trigger new 
erosive lesions in lichen planus.3 This decision, however, 
impeeded the performance of histopathological 
evaluations. Therefore, we investigated the treatment 
results subjectively using the VAS and objectively 
using Thongprasom scoring. One limitation of our 
study is the fact that the systemic absorption of the 
corticosteroid on the contralateral lesion area has 
unknown side effects. However, our study used a split-
mouth design, found in the literature,30 to eliminate 
patient-related factors and to compare lesions with 
similar characteristics. Another limitation of our 
study is the fluctuation of i-PRF doses resulting from 
imprecise nature of centrifugation.
Conclusion
Within the limitations of our study, the pain 
and satisfaction values were positively affected by 
both i-PRF and corticosteroid treatments, and the 
quality of life increased after the procedures. These 
results suggest that i-PRF may be beneficial in the 
treatment of EOLP lesions. Although it cannot be 
considered a first-choice treatment, the i-PRF may be 
considered an alternative therapy in patients who are 
unresponsive to topical corticosteroids. Biochemical 
and histopathological studies should be conducted in 
larger populations to reveal the mechanism of i-PRF 
action in EOLP treatment. 
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